Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SR Medical Technology CoGRLIF 43 EV-to-EBITDA is -445.52 as of Sep. 05, 2026. GuruFocus rates GRLIF with a GF Score™ of 43/100. The stock has 6 warning signs investors should review. Among 1,379 Real Estate companies, SR Medical Technology Co ranks worse than 72516.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SR Medical Technology Co's enterprise value is $1,096.87 Mil.
SR Medical Technology Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.46 Mil. Therefore, SR Medical Technology Co's EV-to-EBITDA for today is -445.52.
The historical rank and industry rank for SR Medical Technology Co's EV-to-EBITDA or its related term are showing as below:
GRLIF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -451.47 Med: 27.17 Max: 741.55
Current: -433.54
During the past 13 years, the highest EV-to-EBITDA of SR Medical Technology Co was 741.55. The lowest was -451.47. And the median was 27.17.
GRLIF's EV-to-EBITDA is ranked worse than 100% of 1379
companies
in the Real Estate industry
Industry Median: 12.18
vs GRLIF: -433.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SR Medical Technology Co (OTCPK:GRLIF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SR Medical Technology Co's PE Ratio (TTM) for today is calculated as:
SR Medical Technology Co's share price for today is $0.21.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SR Medical Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Real Estate Services subindustry, SR Medical Technology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SR Medical Technology Co EV-to-EBITDA vs Real Estate Industry
For the Real Estate industry and Real Estate sector, SR Medical Technology Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SR Medical Technology Co's EV-to-EBITDA falls into.
SR Medical Technology Co's current Enterprise Value is $1,096.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SR Medical Technology Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SR Medical Technology Co (GRLIF) has a EV-to-EBITDA of -445.52 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SR Medical Technology Co. According to the industry distribution chart, SR Medical Technology Co ranks #999999 out of 1379 companies in the Real Estate industry.
Is SR Medical Technology Co's EV-to-EBITDA too high?
SR Medical Technology Co's current EV-to-EBITDA is -445.52. Based on the distribution chart, SR Medical Technology Co ranks #999999 out of 1379 companies in the Real Estate industry, which is in the bottom quartile relative to peers. Overall, SR Medical Technology Co has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does SR Medical Technology Co's EV-to-EBITDA compare to CBRE and BEKE?
According to the Real Estate industry distribution chart, SR Medical Technology Co ranks #999999 out of 1379 companies for EV-to-EBITDA. This places SR Medical Technology Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Real Estate company?
The median EV-to-EBITDA among Real Estate companies is 12.18, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SR Medical Technology Co. For the Real Estate industry, the median EV-to-EBITDA is 12.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SR Medical Technology Co's current EV-to-EBITDA is -445.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SR Medical Technology Co stock overvalued right now?
SR Medical Technology Co (GRLIF) has a current EV-to-EBITDA of -445.52. The current EV-to-EBITDA is -445.52. SR Medical Technology Co's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SR Medical Technology Co (GRLIF), the current EV-to-EBITDA is -445.52 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GR Life Style Co Ltd is an investment holding company. The Group is principally engaged in the property development and investments in the PRC, the USA and the UK, and the provision of property management services in the PRC. The Group has two reportable operating segments: the property development and investment segment, which engages in property development and investment in the UK, the USA and Chinese Mainland; and the property management segment, which engages in the provision of property management and other services for office buildings, residential properties and car parks in Chinese Mainland. The Group operates in Chinese Mainland with maximum revenue, the UK, and the USA.
43GF Score
Get the complete analysis for GRLIF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRLIF has been successfully added to your 
